TG Therapeutics Shares Surge 7% as Multiple Sclerosis Drug Sales Grow

TG Therapeutics (TGTX) shares climbed 7% on Monday, following the company's announcement of strong sales growth for its multiple sclerosis drug, BRIUMVI. The company reported preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively, which far exceeded initial expectations. This robust financial performance indicates the success of BRIUMVI in the market and the company's ability to execute on its growth strategy.



TG Therapeutics also provided an update on its subcutaneous BRIUMVI work, which is expected to allow for the commencement of a pivotal program in 2025, evaluating a self-administered subcutaneous product with an expected dosing frequency of at least every other month. This product profile is believed to be attractive to patients and healthcare providers, further boosting investor confidence in the company's future prospects. Additionally, the company's full year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million, demonstrates the company's ambitious growth plans and potential for continued success.



The multiple sclerosis drugs market size has grown strongly in recent years, driven by factors such as the increasing prevalence of the disease, heightened investments from pharmaceutical companies, and a growing awareness and understanding of multiple sclerosis within the medical community and among the general population. This growth trend is expected to continue in the coming years, fueled by enhanced access to clinical trials, targeted therapies, a rising emphasis on preventive healthcare, increased demand for biosimilars, wider global market penetration, and the integration of combination therapies.

Government and non-government organizations contribute significantly to the growth of the multiple sclerosis drugs market by supporting various programs and initiatives aimed at improving the quality of life for those affected by multiple sclerosis. For example, the joint investment of $1 million by the government of Alberta and Canada's Department of Economic Development, Trade, and Tourism for the Canadian Prospective Cohort Study on MS (CanProCo) gathered $10 million for research and innovations, uniting nearly 50 MS researchers across disciplines in Canada. This financial backing drives the expansion of the multiple sclerosis drugs market.

The escalating prevalence of multiple sclerosis stands as a pivotal factor propelling the growth of the multiple sclerosis drug market. MS is an autoimmune disease impacting the central nervous system, requiring pharmaceutical intervention for symptom management and disease progression. An article from Pace Hospitals in May 2023 highlighted a global MS patient count of 2.8 million, at a rate of 35.9 per 100,000 individuals, with an annual incidence of 2.1 cases per 100,000 people across 75 reporting countries. The disease typically affects individuals around the age of 32 and shows a higher prevalence among females. This increasing prevalence is set to drive the expansion of the multiple sclerosis drug market.

In conclusion, TG Therapeutics' strong sales growth for its multiple sclerosis drug, BRIUMVI, has contributed positively to the company's overall financial performance and has driven a 7% increase in its share price. The company's ambitious growth plans, coupled with the expanding multiple sclerosis drugs market, position TG Therapeutics well for continued success in the future. Investors should closely monitor the company's progress and consider adding TGTX to their portfolios as a potential growth opportunity in the healthcare sector.